VELCADE | Home

VELCADE was the first medicine in more than 10 years approved by the FDA for the treatment of patients with multiple myeloma. Multiple myeloma is a cancer of plasma cells, a particular type of cell found in the marrow of your bones. Multiple myeloma causes the bone marrow to produce too many abnormal plasma cells.

About 20,000 people are diagnosed with multiple myeloma every year in the United States, making it the second most common type of blood cancer. Learn more about VELCADE and Multiple Myeloma >¹

For patients with
mantle cell lymphoma

VELCADE is the only medicine the FDA has approved to treat patients with mantle cell lymphoma who have received at least 1 prior therapy. Mantle cell lymphoma is a cancer of a particular type of cell called a lymphocyte.

About 3,500 people are diagnosed with the disease each year in the United States. Learn more about VELCADE and Mantle Cell Lymphoma >^{2, 3}

National Cancer Institute. Multiple myeloma and other plasma cell neoplasms: treatment (PDQ®)—patient version. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/patient. Accessed February 2, 2009.
Data on file. Millennium Pharmaceuticals, Inc.
Lymphoma Research Foundation. Facts on mantle cell lymphoma. Available at: http://www.lymphoma.org/site/pp.aspx?c=chKOI6PEImE&b=1574381&printmode=1. Accessed November 29, 2007. About Lymphoma http://www.lymphoma.org/site/pp.asp?c=chKOI6PEImE&b=2249267. Accessed January 8, 2008. Non-Hodgkin Lymphoma http://www.lymphoma.org/site/pp.asp?c=chKOI6PEImE&b=1573333. Accessed January 8, 2008. Diagnosing Non-Hodgkin’s Lymphoma http://www.lymphoma.org/site/pp.asp?c=chKOI6PEImE&b=1573965. Accessed January 8, 2008. CancerBackUp. Mantle cell lymphoma. Available at: http://www.cancerbackup.org.uk/Cancertype/Lymphomanon-Hodgkin/TypesofNHL/Mantlecell. Accessed November 13, 2007.